Brain Tumor Drugs Market Outlook (2023 to 2033)

The brain tumor drugs market is estimated to record a 9.2% CAGR from 2023 to 2033. The market is likely to reach US$ 2.65 billion in 2023 and is expected to be worth US$ 6.30 billion in 2033.

Report Attribute Details
Brain Tumor Drugs Market Value (2023) US$ 2.65 billion
Brain Tumor Drugs Market Anticipated Value (2033) US$ 6.30 billion
Brain Tumor Drugs Market Growth Rate (2023 to 2033) 9.2% CAGR

Surging Neurological Condition to Increase the Demand

Rising awareness of neurological illnesses in children and adults is boosting the brain tumor drugs market. Brain illnesses, which include several neurodegenerative, psychiatric, and developmental problems, are the reasons for death associated with brain damage worldwide. According to the American Medical Association (AMA), more than 20% of the world's population is expected to be 65 years or older by 2050.

Cancer, a global public health issue, ranks second in the cause of morbidity in the United States. The global elderly population and the emergence of novel diseases are expected to drive growth in the brain tumor medication market.

The brain tumor medication tackles abnormal cell growth in the brain and is administered in combination or alone, depending on their location, shape, and size. For example, Temozolomide, Avastin, and BiCNU carmustine are medications used to treat brain tumors. Government initiatives and increased knowledge about medical breakthroughs are expected to propel the industry growth in the coming years.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Brain Tumor Drugs Market Outlook in Comparison to 2023 to 2033 Growth Forecast

The brain tumor drugs market was worth US$ 2.52 billion in 2022, at a 9% CAGR from 2017 to 2022.

Developments in medical treatment and advanced patient care for brain illnesses are available globally. Experiments and advancements in combination therapy with current and novel medications have resulted in people suffering from brain tumor problems.

The increased use of targeted therapeutics may restrain market growth. The pharmaceutical industry is focused on developing drugs that specifically target the eradication of cancer cells while causing no harm to normal bodily cells, as some cancer spread to the brain through different body parts. Bevacizumab, for example, prevents cancer cell replication, allowing cytotoxic chemotherapy medications that limit normal cell division to be used. Furthermore, the growing acceptability of these procedures and therapies is anticipated to create roadblocks in the use of traditional brain tumor medications, threatening market expansion.

Historical CAGR (2017 to 2022) 9%
Forecast CAGR (2023 to 2033) 9.2%
  • Short Term (2023 to 2026): The increasing prevalence of neurological disorders worldwide is the primary driving factor responsible for the growth of the brain tumor market.
  • Medium Term (2026 to 2029): Prolonged life expectancy, increased virus exposure, and sedentary lifestyle, neurological illnesses have been highlighted as one of the most prevalent disorders.
  • Long Term (2029 to 2033): Researchers are working on new techniques to diagnose a brain tumor, such as biomarker tests that can estimate a patient’s prognosis.

As per the FMI analysts, a valuation of US$ 6.30 billion by 2033 is estimated for the market.

Year Market Value
2016 US$ 1.43 billion
2021 US$ 2.23 billion
2022 US$ 2.52 billion
2023 US$ 2.65 billion
2033 US$ 6.30 billion

Increased Incidence of Brain Cancer Cases to Drive Market Growth

Factors such as changing lifestyles and eating choices increased urbanization, and smoking habit is surging the cases of brain conditions among adults and elderly people. According to the WHO, nearly 23.0% of adults used tobacco in 2020. As a result, the increased incidence of smoking among adults contributes to the global increase in cancer cases.Furthermore, as the prevalence of various cancer kinds rises, so does the rate of diagnosis and treatment. For example, according to GLOBOCAN, roughly 19,300,000 persons worldwide were diagnosed with cancer in 2020.

Brain tumors account for around 1% to 2% of cancer death in the United States, with a significant fatality rate. The increased occurrence of brain tumors is due to factors such as strong radiation exposure that causes DNA to change and eventually lead to cancer.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Research and Development Pipeline for Novel Treatments

The rising prevalence of brain cancer and rising diagnosis rates, particularly in industrialized nations, are creating a pool of patients in need of treatment. This, together with market participants' increased focus on research and development activities to introduce new medications with clinical benefits for the treatment and management of the illness, is propelling the brain tumor pharmaceuticals market forward.

Unmet needs, such as the availability of these medications on the market, associated with the various stages of brain cancer management, may aid in shifting research and development priorities and improving physicians' therapeutic approaches. As a result, many pharmaceutical companies are investing in research and development to find novel medications for the treatment of brain tumors.

High Treatment Costs along with Limited Reimbursement, are expected to Slow Market Growth

Several side effects associated with brain tumor treatments, as well as the high costs of these drugs, are a few reasons restricting market expansion. Furthermore, lower brain tumor diagnosis and treatment rates, as well as limited reimbursement for these medications in underdeveloped countries, are projected to restrain market growth.

Brain cancer diagnosis and treatment rates are substantially lower in emerging countries than in developed countries. In China, for example, the prevalence of brain tumors was 14.82 per 100,000 individuals in 2021.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Advancement in Brain Tumor Diagnosis to Support Market Growth

Early detection and treatment of brain tumors are difficult due to variables such as the body's blood-brain barrier, which normally protects the spinal cord and brain from harmful substances. This barrier, however, also keeps many forms of chemotherapy out. Thus, improved methods for brain tumor diagnosis and treatment are required. The prevalence of brain tumors is steadily growing, which can be ascribed to advancements in detection and treatment procedures.

Prognostic indicators are vital in the creation of tailored medications and in increasing the survival rate of persons with brain tumors. Neurological and neuroimaging studies are utilized to diagnose glioma at an advanced stage. Assessment of genetic characteristics in biopsy specimens of brain tumor patients is one of the important tools for improved diagnosis and treatment of brain tumors. Furthermore, circulating nucleic acid in the blood and other biological fluids can be employed as a marker for the early detection and treatment of brain tumors.

Success Rates of Immunotherapy May Drive Market Growth

Immunotherapy is a cancer treatment that aids the immune system in its battle against cancer. Immunotherapies are employed in a range of cancer treatments. Immunotherapy holds promise for treating brain cancer, which has traditionally been treated with chemotherapy, radiation therapy, and surgery. Immunotherapy, often known as biological treatment, uses living organisms to treat disease.

Vaccines are a promising new type of immunotherapy that boosts the immune system's ability to fight cancer. This market's growth is expected to be fueled by novel immunotherapy treatments for brain cancer. Furthermore, there are numerous authorized immunotherapies for various brain malignancies, and industry companies and universities are heavily working on researching and marketing new brain tumor immunotherapies.

As a result, this market may grow as universities increase their efforts to develop novel immunotherapy treatments. As a result, the aforementioned factors have contributed to the market's overall expansion.

Market is likely to be Dominated by North America

The North American brain tumor market is expected to grow significantly during the forecast period. The United States is expected to lead the market because of its developed healthcare industry and increased awareness of sophisticated technologies among the populace in this area.

According to the American Brain Tumor Association, about 84,000 people were diagnosed with a primary brain tumor in 2021, and roughly 18,000 died as a result of a primary malignant brain tumor. Furthermore, more than 28,000 youngsters in the United States were diagnosed with a brain tumor in 2021, according to the same source.

The increased occurrence of brain tumors is likely to boost regional growth. Furthermore, the market analyzed in the United States is projected to be driven by regular product releases and pharmacological approvals, as well as considerable R&D initiatives for the treatment of brain tumors.

The surging clinical trials for brain tumor therapy in the United States are likely to boost the expansion of this market. As a result of the foregoing factors, the North American brain tumor drugs market is expected to expand significantly over the forecast period.

The market in Latin America is expanding due to an increase in brain tumor diagnosis and treatment, which has created a demand for these medications in the region. This, combined with the introduction of new pharmaceuticals in the region, is contributing to the region's market growth.

Common CNS Cancer in Europe Boosts the Market

The frequency of primary brain tumors, favorable regulatory circumstances in leading European nations, and an increased emphasis on research activities for producing brain tumor drugs are driving the market in Europe.

According to national and regional estimates, around US$ 115.00 billion was spent on cancer care in Europe in 2019, with direct expenditures on cancer medications accounting for nearly US$ 35.00 to US$ 40.00 billion.

Market in Asia Pacific is expected to Accelerate due to Rising Awareness

The market in the Asia Pacific is influenced by rising awareness of brain cancer, early detection, and increased clinical trial in drug delivery for brain cancer cells. Furthermore, increased knowledge regarding brain tumors and their forms in the region boosts the market growth.

According to brain tumor research, the average rating of brain tumor care in Australia was the lowest of all cancers, with a score of 8.37 out of 10. Moreover, in 2018, nearly two thousand people died due to brain cancer in the Asia Pacific.

Competitive Landscape

Prominent Participants in the Market

  • AstraZeneca plc
  • Johnson & Johnson Inc
  • Merck & Co
  • Pfizer Inc
  • F. Hoffmann-La Roche Ltd
  • Y-mAbs Therapeutics, Inc
  • Shimadzu Corporation
  • Bristol-Myers Squibb
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd
  • Among others

Scope of Report

Attribute Details
Market Size Value in 2023 US$ 2.65 billion
Market Size Value in 2033 US$ 6.30 billion
Market Analysis US$ billion for Value
Key Region Covered North America; Latin America; Europe; Asia Pacific; The Middle East and Africa
Key Segments By Therapy, By Indication, By Distribution Channel, By Region
Key Companies Profiled AstraZeneca plc; Johnson & Johnson Inc; Merck & Co; Pfizer Inc; F. Hoffmann-La Roche Ltd; Y-mAbs Therapeutics, Inc; Shimadzu Corporation; Bristol-Myers Squibb; Bayer AG; Dr. Reddy's Laboratories Ltd; Among others
Report Coverage Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing Available upon Request

Key Segment

By Therapy:

  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Others

By Indication:

  • Pituitary
  • Meningioma
  • Glioma
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail & Online Pharmacy

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • The Middle East and Africa

Frequently Asked Questions

What is the Key Driver of the Brain Tumor Drugs Market?

Surging neurological condition is the key driver of the market.

Which Factor is Restraining the Market Growth?

The increased use of targeted therapeutics may restrain the market growth.

What will be the Growth Rate until 2033?

The market is likely to experience a 9.2% CAGR until 2033.

What is the Estimated Market Value in 2033?

The market is predicted to be worth US$ 6.30 billion in 2033.

Which Region will Dominate the Market?

North America is likely to dominate the market.

Table of Content
1. Executive Summary | Brain Tumor Drugs Market
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
        5.3.1. Temozolomide
        5.3.2. Carmustine
        5.3.3. Cisplatin
        5.3.4. Bevacizumab
        5.3.5. Geftinib
        5.3.6. Erlotinib
    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033
        6.3.1. Targeted Therapy
        6.3.2. Chemotherapy
        6.3.3. Immunotherapy
    6.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022
    6.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By Indication , 2018 to 2022
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication , 2023 to 2033
        7.3.1. Pituitary Tumor
        7.3.2. Meningioma
        7.3.3. Glioblastoma
    7.4. Y-o-Y Growth Trend Analysis By Indication , 2018 to 2022
    7.5. Absolute $ Opportunity Analysis By Indication , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    8.1. Introduction / Key Findings
    8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
    8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    9.1. Introduction
    9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
    9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
        9.3.1. North America
        9.3.2. Latin America
        9.3.3. Europe
        9.3.4. South Asia
        9.3.5. East Asia
        9.3.6. Oceania
        9.3.7. MEA
    9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        10.2.1. By Country
            10.2.1.1. USA
            10.2.1.2. Canada
        10.2.2. By Drug Class
        10.2.3. By Therapy
        10.2.4. By Indication
        10.2.5. By Distribution Channel
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Drug Class
        10.3.3. By Therapy
        10.3.4. By Indication
        10.3.5. By Distribution Channel
    10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        11.2.1. By Country
            11.2.1.1. Brazil
            11.2.1.2. Mexico
            11.2.1.3. Rest of Latin America
        11.2.2. By Drug Class
        11.2.3. By Therapy
        11.2.4. By Indication
        11.2.5. By Distribution Channel
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Drug Class
        11.3.3. By Therapy
        11.3.4. By Indication
        11.3.5. By Distribution Channel
    11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        12.2.1. By Country
            12.2.1.1. Germany
            12.2.1.2. United kingdom
            12.2.1.3. France
            12.2.1.4. Spain
            12.2.1.5. Italy
            12.2.1.6. Rest of Europe
        12.2.2. By Drug Class
        12.2.3. By Therapy
        12.2.4. By Indication
        12.2.5. By Distribution Channel
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Drug Class
        12.3.3. By Therapy
        12.3.4. By Indication
        12.3.5. By Distribution Channel
    12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        13.2.1. By Country
            13.2.1.1. India
            13.2.1.2. Malaysia
            13.2.1.3. Singapore
            13.2.1.4. Thailand
            13.2.1.5. Rest of South Asia
        13.2.2. By Drug Class
        13.2.3. By Therapy
        13.2.4. By Indication
        13.2.5. By Distribution Channel
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Drug Class
        13.3.3. By Therapy
        13.3.4. By Indication
        13.3.5. By Distribution Channel
    13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        14.2.1. By Country
            14.2.1.1. China
            14.2.1.2. Japan
            14.2.1.3. South Korea
        14.2.2. By Drug Class
        14.2.3. By Therapy
        14.2.4. By Indication
        14.2.5. By Distribution Channel
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Drug Class
        14.3.3. By Therapy
        14.3.4. By Indication
        14.3.5. By Distribution Channel
    14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        15.2.1. By Country
            15.2.1.1. Australia
            15.2.1.2. New Zealand
        15.2.2. By Drug Class
        15.2.3. By Therapy
        15.2.4. By Indication
        15.2.5. By Distribution Channel
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Drug Class
        15.3.3. By Therapy
        15.3.4. By Indication
        15.3.5. By Distribution Channel
    15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        16.2.1. By Country
            16.2.1.1. GCC Countries
            16.2.1.2. South Africa
            16.2.1.3. Israel
            16.2.1.4. Rest of MEA
        16.2.2. By Drug Class
        16.2.3. By Therapy
        16.2.4. By Indication
        16.2.5. By Distribution Channel
    16.3. Market Attractiveness Analysis
        16.3.1. By Country
        16.3.2. By Drug Class
        16.3.3. By Therapy
        16.3.4. By Indication
        16.3.5. By Distribution Channel
    16.4. Key Takeaways
17. Key Countries Market Analysis
    17.1. USA
        17.1.1. Pricing Analysis
        17.1.2. Market Share Analysis, 2022
            17.1.2.1. By Drug Class
            17.1.2.2. By Therapy
            17.1.2.3. By Indication
            17.1.2.4. By Distribution Channel
    17.2. Canada
        17.2.1. Pricing Analysis
        17.2.2. Market Share Analysis, 2022
            17.2.2.1. By Drug Class
            17.2.2.2. By Therapy
            17.2.2.3. By Indication
            17.2.2.4. By Distribution Channel
    17.3. Brazil
        17.3.1. Pricing Analysis
        17.3.2. Market Share Analysis, 2022
            17.3.2.1. By Drug Class
            17.3.2.2. By Therapy
            17.3.2.3. By Indication
            17.3.2.4. By Distribution Channel
    17.4. Mexico
        17.4.1. Pricing Analysis
        17.4.2. Market Share Analysis, 2022
            17.4.2.1. By Drug Class
            17.4.2.2. By Therapy
            17.4.2.3. By Indication
            17.4.2.4. By Distribution Channel
    17.5. Germany
        17.5.1. Pricing Analysis
        17.5.2. Market Share Analysis, 2022
            17.5.2.1. By Drug Class
            17.5.2.2. By Therapy
            17.5.2.3. By Indication
            17.5.2.4. By Distribution Channel
    17.6. United kingdom
        17.6.1. Pricing Analysis
        17.6.2. Market Share Analysis, 2022
            17.6.2.1. By Drug Class
            17.6.2.2. By Therapy
            17.6.2.3. By Indication
            17.6.2.4. By Distribution Channel
    17.7. France
        17.7.1. Pricing Analysis
        17.7.2. Market Share Analysis, 2022
            17.7.2.1. By Drug Class
            17.7.2.2. By Therapy
            17.7.2.3. By Indication
            17.7.2.4. By Distribution Channel
    17.8. Spain
        17.8.1. Pricing Analysis
        17.8.2. Market Share Analysis, 2022
            17.8.2.1. By Drug Class
            17.8.2.2. By Therapy
            17.8.2.3. By Indication
            17.8.2.4. By Distribution Channel
    17.9. Italy
        17.9.1. Pricing Analysis
        17.9.2. Market Share Analysis, 2022
            17.9.2.1. By Drug Class
            17.9.2.2. By Therapy
            17.9.2.3. By Indication
            17.9.2.4. By Distribution Channel
    17.10. India
        17.10.1. Pricing Analysis
        17.10.2. Market Share Analysis, 2022
            17.10.2.1. By Drug Class
            17.10.2.2. By Therapy
            17.10.2.3. By Indication
            17.10.2.4. By Distribution Channel
    17.11. Malaysia
        17.11.1. Pricing Analysis
        17.11.2. Market Share Analysis, 2022
            17.11.2.1. By Drug Class
            17.11.2.2. By Therapy
            17.11.2.3. By Indication
            17.11.2.4. By Distribution Channel
    17.12. Singapore
        17.12.1. Pricing Analysis
        17.12.2. Market Share Analysis, 2022
            17.12.2.1. By Drug Class
            17.12.2.2. By Therapy
            17.12.2.3. By Indication
            17.12.2.4. By Distribution Channel
    17.13. Thailand
        17.13.1. Pricing Analysis
        17.13.2. Market Share Analysis, 2022
            17.13.2.1. By Drug Class
            17.13.2.2. By Therapy
            17.13.2.3. By Indication
            17.13.2.4. By Distribution Channel
    17.14. China
        17.14.1. Pricing Analysis
        17.14.2. Market Share Analysis, 2022
            17.14.2.1. By Drug Class
            17.14.2.2. By Therapy
            17.14.2.3. By Indication
            17.14.2.4. By Distribution Channel
    17.15. Japan
        17.15.1. Pricing Analysis
        17.15.2. Market Share Analysis, 2022
            17.15.2.1. By Drug Class
            17.15.2.2. By Therapy
            17.15.2.3. By Indication
            17.15.2.4. By Distribution Channel
    17.16. South Korea
        17.16.1. Pricing Analysis
        17.16.2. Market Share Analysis, 2022
            17.16.2.1. By Drug Class
            17.16.2.2. By Therapy
            17.16.2.3. By Indication
            17.16.2.4. By Distribution Channel
    17.17. Australia
        17.17.1. Pricing Analysis
        17.17.2. Market Share Analysis, 2022
            17.17.2.1. By Drug Class
            17.17.2.2. By Therapy
            17.17.2.3. By Indication
            17.17.2.4. By Distribution Channel
    17.18. New Zealand
        17.18.1. Pricing Analysis
        17.18.2. Market Share Analysis, 2022
            17.18.2.1. By Drug Class
            17.18.2.2. By Therapy
            17.18.2.3. By Indication
            17.18.2.4. By Distribution Channel
    17.19. GCC Countries
        17.19.1. Pricing Analysis
        17.19.2. Market Share Analysis, 2022
            17.19.2.1. By Drug Class
            17.19.2.2. By Therapy
            17.19.2.3. By Indication
            17.19.2.4. By Distribution Channel
    17.20. South Africa
        17.20.1. Pricing Analysis
        17.20.2. Market Share Analysis, 2022
            17.20.2.1. By Drug Class
            17.20.2.2. By Therapy
            17.20.2.3. By Indication
            17.20.2.4. By Distribution Channel
    17.21. Israel
        17.21.1. Pricing Analysis
        17.21.2. Market Share Analysis, 2022
            17.21.2.1. By Drug Class
            17.21.2.2. By Therapy
            17.21.2.3. By Indication
            17.21.2.4. By Distribution Channel
18. Market Structure Analysis
    18.1. Competition Dashboard
    18.2. Competition Benchmarking
    18.3. Market Share Analysis of Top Players
        18.3.1. By Regional
        18.3.2. By Drug Class
        18.3.3. By Therapy
        18.3.4. By Indication
        18.3.5. By Distribution Channel
19. Competition Analysis
    19.1. Competition Deep Dive
        19.1.1. Genetech USAA
            19.1.1.1. Overview
            19.1.1.2. Product Portfolio
            19.1.1.3. Profitability by Market Segments
            19.1.1.4. Sales Footprint
            19.1.1.5. Strategy Overview
                19.1.1.5.1. Marketing Strategy
        19.1.2. Bristol Myers Squibb
            19.1.2.1. Overview
            19.1.2.2. Product Portfolio
            19.1.2.3. Profitability by Market Segments
            19.1.2.4. Sales Footprint
            19.1.2.5. Strategy Overview
                19.1.2.5.1. Marketing Strategy
        19.1.3. Hoffmann- La Roche
            19.1.3.1. Overview
            19.1.3.2. Product Portfolio
            19.1.3.3. Profitability by Market Segments
            19.1.3.4. Sales Footprint
            19.1.3.5. Strategy Overview
                19.1.3.5.1. Marketing Strategy
        19.1.4. AstraZeneca Plc.
            19.1.4.1. Overview
            19.1.4.2. Product Portfolio
            19.1.4.3. Profitability by Market Segments
            19.1.4.4. Sales Footprint
            19.1.4.5. Strategy Overview
                19.1.4.5.1. Marketing Strategy
        19.1.5. Pfizer Inc.
            19.1.5.1. Overview
            19.1.5.2. Product Portfolio
            19.1.5.3. Profitability by Market Segments
            19.1.5.4. Sales Footprint
            19.1.5.5. Strategy Overview
                19.1.5.5.1. Marketing Strategy
        19.1.6. Novartis AG
            19.1.6.1. Overview
            19.1.6.2. Product Portfolio
            19.1.6.3. Profitability by Market Segments
            19.1.6.4. Sales Footprint
            19.1.6.5. Strategy Overview
                19.1.6.5.1. Marketing Strategy
        19.1.7. Antisense Pharma
            19.1.7.1. Overview
            19.1.7.2. Product Portfolio
            19.1.7.3. Profitability by Market Segments
            19.1.7.4. Sales Footprint
            19.1.7.5. Strategy Overview
                19.1.7.5.1. Marketing Strategy
        19.1.8. Merck & Co
            19.1.8.1. Overview
            19.1.8.2. Product Portfolio
            19.1.8.3. Profitability by Market Segments
            19.1.8.4. Sales Footprint
            19.1.8.5. Strategy Overview
                19.1.8.5.1. Marketing Strategy
        19.1.9. MacLeod’s Pharmaceutical Limited
            19.1.9.1. Overview
            19.1.9.2. Product Portfolio
            19.1.9.3. Profitability by Market Segments
            19.1.9.4. Sales Footprint
            19.1.9.5. Strategy Overview
                19.1.9.5.1. Marketing Strategy
        19.1.10. Mankind Pharma
            19.1.10.1. Overview
            19.1.10.2. Product Portfolio
            19.1.10.3. Profitability by Market Segments
            19.1.10.4. Sales Footprint
            19.1.10.5. Strategy Overview
                19.1.10.5.1. Marketing Strategy
        19.1.11. Siemens Healthineers AG
            19.1.11.1. Overview
            19.1.11.2. Product Portfolio
            19.1.11.3. Profitability by Market Segments
            19.1.11.4. Sales Footprint
            19.1.11.5. Strategy Overview
                19.1.11.5.1. Marketing Strategy
        19.1.12. Dr. Reddy’s Laboratories Ltd.
            19.1.12.1. Overview
            19.1.12.2. Product Portfolio
            19.1.12.3. Profitability by Market Segments
            19.1.12.4. Sales Footprint
            19.1.12.5. Strategy Overview
                19.1.12.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Recommendations

Healthcare

Brain Tumor Treatment Market

July 2023

REP-GB-1302

325 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Brain Tumor Drugs Market

Schedule a Call